Amendment: SEC Form SC TO-T/A filed by MorphoSys AG

$MOR
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $MOR alert in real time by email

Weekly insight reads limit reached.

Join Quantisnow to enjoy unlimited reads, alerts, live feeds, and more.

Meet Quantisnow

Stock alerts. Live news feeds. Press releases. Insider trading. FDA approvals & more.

Invest smarter

A better trading workflow

Access market-moving news before they break out to the general public. Let Quantisnow cut out the noise and only receive insights that matter.

Live feeds
Real-time news feeds for Press Releases, SEC Filings, FDA approvals, market insights and more.
Custom filters
Filter out the noise with company filters, market cap filters, price filters and more.
Audio Squawk
Multitask with confidence and let Quantsinow read breaking news out loud.
Product screenshot
Quantisnow AI Features

Save time

Unlock Insights with AI

Get quick summaries and precise Q&A for every insight, empowering you to make informed decisions without sifting through entire press releases and lengthy SEC filings.

Get alerted immediately

All your stock market alerts in one place

Quantisnow alerts are fast, customizable, and versatile.

Email alerts
Subscribe to your favorite stocks and receive email alerts each time a news pops up.
App notifications
Reduce alerting latency with in-app notifications. Same as email alerts, but faster.
Webhooks
Integrate with Quantisnow programmatically and receive live insights via webhooks
Granular alerts
Want to receive Press Releases but no SEC filings? No problem - Quantisnow alerts are highly customizable and can seemlessly tailor to your trading needs.

Elevate your trading.
Start using Quantisnow today.

Never miss an update.

App screenshot

Simple no-tricks pricing

One membership with full access and no delays.

Quantisnow Plus

Your personal trading assistant for just $39/month.

What's included

  • Live feeds
  • Audio squawk
  • Compact mode in feeds
  • Email alerts
  • App push alerts
  • Unlimited insights reads
  • Unlimited subscriptions
  • Advanced filters in live feeds
  • Support
  • No ads
  • AI-generated summaries and Q&A

One membership - all access

$39/month

Get access

$39/month with yearly billing, $49/month with monthly billing

News insights ingested and delivered in real time
5 million+
Real-time news alerts sent out to Quantisnow users
700,000+
Latency of news delivery pipelines to users via mobile app, webhooks, and email
<100ms
Get the next $MOR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MOR

DatePrice TargetRatingAnalyst
3/14/2024Overweight → Equal Weight
Wells Fargo
1/16/2024$9.19 → $10.40Overweight → Equal-Weight
Morgan Stanley
10/13/2023$3.70 → $9.19Underweight → Overweight
Morgan Stanley
9/15/2023$3.50 → $9.25Sell → Neutral
Goldman
7/17/2023Sell → Hold
Deutsche Bank
6/16/2023$3.30 → $10.00Underweight → Overweight
JP Morgan
6/16/2023$17.00Overweight
Wells Fargo
5/31/2023Buy
UBS
More analyst ratings

$MOR
Press Releases

Fastest customizable press release news feed in the world

See more
  • Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting

    MUNICH, GERMANY / ACCESSWIRE / August 27, 2024 / MorphoSys AG today announced that its shareholders approved all resolutions proposed by the company's Management Board and Supervisory Board at its 2024 Annual General Meeting. This included the transfer of MorphoSys' minority shareholders' shares to Novartis BidCo Germany AG (hereinafter referred to as "Novartis"), the company's majority shareholder, against a cash compensation of € 68.00 per share ("merger squeeze-out"). The merger squeeze-out will become effective once the transfer resolution and merger have been registered in the commercial register of MorphoSys, and the merger has also been registered in the commercial register of Novarti

    $MOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market

    MorphoSys AG ((FSE: MOR, NASDAQ:MOR) today announced that it has formally notified the Nasdaq Stock Market of its intention to voluntarily delist its American Depositary Shares ("ADSs") from the Nasdaq Global Market and to deregister the ADSs under Section 12(b) of the Securities Exchange Act of 1934 (the "Exchange Act"). MorphoSys currently anticipates that it will file with the Securities and Exchange Commission (the "SEC") a Form 25, Notification of Removal of Listing and/or Registration Under Section 12(b) of the Exchange Act, relating to the delisting and deregistration on or about July 25, 2024, with the delisting of the ADSs taking effect no earlier than ten days thereafter. As a r

    $MOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys' Minority Shareholders

    MorphoSys AG ((FSE: MOR, NASDAQ:MOR) today announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024. Novartis BidCo Germany AG (together with Novartis BidCo AG and Novartis AG hereinafter collectively referred to as "Novartis") also informed MorphoSys of their intention to merge MorphoSys into Novartis by initiating a squeeze-out of MorphoSys' minority shareholders. In April 2024, Novartis submitted a voluntary public takeover offer for all outstanding MorphoSys no-par value bearer shares, offering MorphoSys shareholders € 68.00 per share in cash (the "T

    $MOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

$MOR
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$MOR
SEC Filings

See more

$MOR
Leadership Updates

Live Leadership Updates

See more
  • CARsgen Appoints Dr. Sylvie Peltier as Senior Vice President of Global Regulatory Affairs

    SHANGHAI, Oct. 31, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr. Sylvie Peltier ("Dr. Peltier") has been appointed as Senior Vice President of Global Regulatory Affairs of the Company with effect from October 31st, 2022. She will be responsible for developing global regulatory strategies, leading and driving the Company's regulatory affairs activities, and initiatives in support of IND/CTA/BLA filing and approval of developmental products globally. Dr. Peltier has extensive global leadership and hands-on experiences in cl

    $MOR
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • MorphoSys Appoints Tim Demuth as New Chief Research and Development Officer, Following the Retirement of Malte Peters

    Tim Demuth, M.D., Ph.D., has more than 20 years of broad leadership experience in drug development, with a focus in oncology MorphoSys AG ((FSE: MOR, NASDAQ:MOR) announced today that Malte Peters, M.D., the company's Chief Research and Development Officer and Management Board member, has decided to retire at the end of 2022. His successor will be Tim Demuth, M.D., Ph.D., current Chief Medical Officer of Pieris Pharmaceuticals, Inc., a clinical-stage biotechnology company. Tim will start his new role on October 1. He will report to MorphoSys' CEO, Jean-Paul Kress, M.D., and be a member of the company's Executive Committee. At this time, Malte will step down from his operational responsibili

    $MOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • MorphoSys AG Reports Outcome of Annual General Meeting 2022

    PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 18, 2022 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) announced today that its shareholders approved all resolutions proposed by the Company´s Management and Supervisory Boards at the Company´s virtual Annual General Meeting which took place on Wednesday, May 18, 2022, including:- The discharge of the members of the Management and Supervisory Boards with respect to the 2021 financial year- The appointment of PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft as auditor for the 2022 financial year- The election of Mr. Andrew Cheng, M.D., Ph.D., as Supervisory Board member- Resolution on the reduction of Conditional Capital 2016-III, Conditional Ca

    $MOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

$MOR
Financials

Live finance-specific insights

See more
  • MorphoSys AG Reports First Quarter 2024 Financial Results

    – Entered into Business Combination Agreement to be acquired by Novartis for € 68.00 per share in cash, representing a total equity value of € 2.7 billion – Received all mandatory antitrust approvals for the proposed acquisition by Novartis – Shareholder acceptance period for the Novartis offer has commenced and will end on May 13, 2024, at 24:00 hours CEST – Sold all tafasitamab rights worldwide to Incyte – € 631.9 million in cash and other financial assets as of March 31, 2024 MorphoSys AG ((FSE: MOR, NASDAQ:MOR) reports results for the first quarter of 2024. "The proposed acquisition by Novartis is advancing steadily, and we continue to anticipate its closure in the first hal

    $MOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

    – Entered into Business Combination Agreement to be acquired by Novartis for € 68.00 per share in cash or € 2.7 billion equity value – Sold all tafasitamab rights worldwide to Incyte – Presented comprehensive Phase 3 MANIFEST-2 study results at ASH 2023 Annual Meeting, demonstrating pelabresib improves all four disease hallmarks of myelofibrosis – Monjuvi® U.S. net product sales of US$ 24.1 million (€ 22.4 million) for the fourth quarter of 2023 and US$ 92.0 million (€ 85.0 million) for the full year of 2023 – € 680.5 million in cash and other financial assets as of December 31, 2023 – MorphoSys to host conference call and webcast on Thursday, March 14, 2024, at 1:00 pm CET (12:00

    $MOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Invitation to MorphoSys' Full Year Results 2023 Conference Call on March 14, 2024

    Conference Call AlertPLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 7, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the financial year 2023 on March 13, 2024, at 09:00 pm CET (08:00 pm GMT; 04:00 pm EDT).MorphoSys' Management team will host a conference call and webcast on March 14, 2024, at 01:00 pm CET (12:00 pm GMT; 08:00 am EDT) to present the results for the financial year 2023 and provide an outlook for 2024.The conference call will start with a presentation by the Management team followed by a Q&A session.A live webcast and slides will be made available in the Investors section of the MorphoSys' website, www.morphosys.com.To join the conference call via pho

    $MOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

$MOR
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more